Comparisons of SID and EID groups on demographic variables
| SID | Total EID | EED | LED | VED | Within EID | |
|---|---|---|---|---|---|---|
| Participants (n) | 1080 | 894 | 246 | 269 | 379 | |
| Percentage female | 70 | 73* | 79† | 64 | 73 | EED>LED>VED |
| Age | 45.48 (11.48) | 45.59 (11.67) | 48.24† (11.46) | 43.44 (12.04) | 45.40† (11.22) | EED>LED |
| BMI | 27.84 (6.70) | 26.59 (5.63) | 27.00 (5.62) | 25.94 (5.18) | 26.91 (6.02) | |
| JC virus positive | 50% | 63%† | 66%† | 67%† | 58%† | |
| Median JC virus index | 0.22 (0.99) | 0.75 (1.25) | 1.63* (1.36) | 0.69 (1.22) | 0.34* (1.06) | |
| Prior immunosuppressives (%) | 12 | 17 | 9 | 27† | 15† | LED, VED>EED |
| Disease duration | 12.03 (7.39) | 13.22† (7.26) | 13.86† (7.88) | 12.84† (6.48) | 13.09† (7.37) | VED>LED |
| NTZ doses | 27.39 (18.24) | 40.07† (21.66) | 51.62† (27.23) | 33.74† (15.83) | 37.08† (18.06) | EED>VED, LED |
| Total extended duration doses | 24.96 (15.67) | 20.62 (12.66) | 24.92† (14.66) | 27.80† (17.43) |
Means and SDs (in parentheses).
Comparisons in columns 2–5 are to SID group. Comparisons between the three EID groups (EED vs LED vs VED) are displayed in column 6. Comparisons of total extended duration doses were made with the EED group as the reference and VED and LED as dummy variables.
*Indicates EID group differs from SID group at 0.05<p<0.10.
†Indicates EID group differs from SID group at p<0.05.
BMI, body mass index; EED, early extended dosing; EID, extended interval dosing; LED, late extended dosing; NTZ, natalizumab; SID, standard interval dosing; VED, variable extended dosing.